NCT05682638

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 34,000 (estimated)
• Sponsor: AIM Vaccine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Older

Conditions

• SARS-CoV-2

Interventions

Type	Name	Description
BIOLOGICAL	LVRNA009	100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
OTHER	0.9%NaCl	1.0ml/dose, 2 injection with 28 days apart

Timeline

• Start date: 2023-01-30
• Primary completion: 2024-12-01
• Completion: 2025-12-01
• First posted: 2023-01-12
• Last updated: 2023-02-21

Locations

1 site across 1 country: Kenya